Mindset Pharma to Participate in Upcoming Investor Conferences in March 2022

Rhea-AI Summary

Mindset Pharma (OTCQB: MSSTF) announced its participation in three upcoming investor conferences aimed at promoting its next-generation psychedelic medicines for neurological and psychiatric disorders. CEO James Lanthier and CSO Joseph Araujo will represent the company, with Araujo on the Psychedelics: Immunotherapy for the Mind panel at the 34th Annual Roth Conference from March 13-15, 2022. Lanthier will present at Oppenheimer’s Healthcare Conference on March 17, and a corporate presentation will be available during Maxim’s Virtual Growth Conference from March 28-30.

TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that James Lanthier, CEO, and Joseph Araujo, CSO of Mindset, will participate in three upcoming investor conferences:

• 34^th Annual Roth Conference to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California on March 13-15, 2022. Mr. Araujo will participate in the Psychedelics: “Immunotherapy” for the Mind panel on Tuesday, March 15^th at 10:00 a.m. PT.
  
  
• Oppenheimer’s 32nd Annual Healthcare Conference to be held virtually on March 15-17, 2022. Mr. Lanthier will present on Thursday, March 17^th at 12:40 p.m. ET.
  
  
• Maxim’s 2022 Virtual Growth Conference to be held virtually on March 28-30, 2022. Mr. Lanthier’s corporate presentation will be available on-demand. To attend, register here.
  

For more information about the conferences, or to schedule a one-on-one meeting with Mindset management, please contact your appropriate representative directly, or send an email to Roth at pc@roth.com, Oppenheimer at opcoconferences@opco.com, Maxim at jthompson@maximgrp.com, or KCSA Strategic Communications at Mindset@kcsa.com.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
​​
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FAQ

What events is Mindset Pharma participating in during March 2022?

Mindset Pharma is participating in three conferences: 34th Annual Roth Conference on March 13-15, Oppenheimer's Healthcare Conference from March 15-17, and Maxim's Virtual Growth Conference from March 28-30.

Who from Mindset Pharma will speak at the conferences?

CEO James Lanthier and CSO Joseph Araujo will represent Mindset Pharma at the investor conferences.

What is the focus of Mindset Pharma's presentations?

Mindset Pharma focuses on next-generation psychedelic medicines for treating neurological and psychiatric disorders with unmet medical needs.

When is Araujo presenting at the Roth Conference?

Joseph Araujo will present on the Psychedelics: Immunotherapy for the Mind panel on March 15, 2022, at 10:00 a.m. PT.

How can I attend Mindset Pharma's virtual presentations?

To attend Mindset Pharma's virtual presentations, register for Maxim’s Virtual Growth Conference, available on-demand from March 28-30, 2022.